Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Vanderbilt University Medical Center

Sites in Nashville, TN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 8:27 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1272
Shown on this page
12
Current sort
Recently updated
Campus scope
Vanderbilt University Medical Center, Nashville, TN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Vanderbilt University Medical Center, Nashville, TN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 745–756 of 1,272 matching trials with a site at Vanderbilt University Medical Center, Nashville, TN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1 Interventional

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

NCT03816358
Site status not listed — check the official record
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Anetumab Ravtansine, Biopsy Procedure, Biospecimen Collection, Gemcitabine Hydrochloride, Ipilimumab, Nivolumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 1, 2026, 8:27 PM EST
Recruiting Not applicable Interventional

A Study of Electronic Clinical Decision Support Tools for Steatotic Liver Disease

NCT07382349
Status at this site: Recruiting
View directory record Official record
Conditions
MASLD
Interventions
eMPOWER Decision Aid
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
7,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 1, 2026, 8:27 PM EST
Recruiting No phase listed Observational

Prospective Investigation of Cirrhotic Cardiomyopathy in Humans

NCT07658222
Status at this site: Recruiting
View directory record Official record
Conditions
Cirrhotic Cardiomyopathy
Interventions
Not listed
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Nashville, Tennessee • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 1, 2026, 8:27 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

HEALEY ALS Platform Trial - Master Protocol

NCT04297683
Site status not listed — check the official record
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343, NUZ-001
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Nov 1, 2026, 8:27 PM EST
Not yet recruiting Not applicable Interventional

Intervention for Alcohol Use Disorder Recovery After Liver Transplantation

NCT07214259
Site status not listed — check the official record
View directory record Official record
Conditions
Liver Transplant Recipient, Alcohol Use Disorders (AUD)
Interventions
Online Sober Active Community, Recovery coach
Behavioral
Lead sponsor
Leigh Anne Dageforde
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 1, 2026, 8:27 PM EST
Active, not recruiting Phase 2 Interventional Results available

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

NCT03190915
Site status not listed — check the official record
View directory record Official record
Conditions
Juvenile Myelomonocytic Leukemia, Neurofibromatosis Type 1
Interventions
Bone Marrow Aspiration and Biopsy, Trametinib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Month to 21 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 1, 2026, 8:27 PM EST
Active, not recruiting Phase 2 Interventional Results available

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

NCT03414658
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Vinorelbine, Trastuzumab, Avelumab, Utomilumab
Drug
Lead sponsor
Adrienne G. Waks
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
17
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 1, 2026, 8:27 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Registry Study for the Evaluation of High-risk Cardiac Patients by WILLEM AI-based ECG Platform

NCT07333547
Status at this site: Recruiting
View directory record Official record
Conditions
High-risk Cardiac Patients
Interventions
Willem AI ECG assessment
Device
Lead sponsor
Idoven 1903 S.L.
Industry
Eligibility
18 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2036
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 1, 2026, 8:27 PM EST
Active, not recruiting Phase 2Phase 3 Interventional Results available

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

NCT02598661
Site status not listed — check the official record
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Imetelstat Sodium, Placebo
Drug
Lead sponsor
Geron Corporation
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
22
States / cities
Birmingham, Alabama • Tucson, Arizona • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 1, 2026, 8:27 PM EST
Active, not recruiting Phase 3 Interventional

A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

NCT05394116
Site status not listed — check the official record
View directory record Official record
Conditions
Fibrodysplasia Ossificans Progressiva
Interventions
Garetosmab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
2
States / cities
Los Angeles, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 17, 2026 · Synced Nov 1, 2026, 8:27 PM EST
Recruiting Not applicable Interventional

Randomized Trial Comparing Immediate vs. Deferred Surgery for Symptomatic ERM

NCT05145491
Status at this site: Recruiting
View directory record Official record
Conditions
Epiretinal Membrane
Interventions
Immediate Vitrectomy, Deferred Vitrectomy
Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
47
States / cities
Scottsdale, Arizona • Glendale, California • Huntington Beach, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 1, 2026, 8:27 PM EST
Recruiting No phase listed Observational

Prospective Clinical Assessment Study in Children With Hypochondroplasia

NCT06410976
Status at this site: Recruiting
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Not listed
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
30 Months to 16 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 1, 2026, 8:27 PM EST

About this Vanderbilt University Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Vanderbilt University Medical Center in Nashville, TN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.